Spotlight on Internal Medicine
Spotlight Series: Unmet Needs in Hypertension Treatment Options
StartActivity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Activity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Internal Medicine Presentations
Spotlight Series: Unmet Needs in Hypertension Treatment Options
StartActivity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Activity Details
1.0 ABIM MOC point(s)
1.0 ANCC Contact Hour(s)
Expires: January 30, 2024
Accredited By
ACCME (AMA PRA Category 1 Credit™), ANCC
Target Audience
- General Cardiologists
- Nephrologists
- Hypertension Specialists
- Internal Medicine Physicians
- Primary Care/Family Medicine Physicians
- Physician Assistants involved in the care of patients with hypertension
- Nurse Practitioners involved in the care of patients with hypertension
- Nurses involved in the care of patients with hypertension
Learning Objectives
- Recognize established and emerging treatment options for patients with resistant hypertension.
- Identify healthcare disparities in care provided to patients with hypertension.
- Apply shared decision-making strategies to improve health equity by better engaging patients in health care decisions through the development of improved patient-provider communication skills.
Activity Description
Hypertension increases with age and treatment-resistant hypertension exists within the US population.
Participants in this activity will learn about treatment options for patients with resistant hypertension, how to address healthcare disparities in treatment and management, and shared decision-making strategies to improve health equity.
Statement of Educational Need
It is estimated 10.3 million US adults have apparent treatment-resistant hypertension.1 The overall goal of the intervention is to increase healthcare professionals’ (HCP) awareness, knowledge, and competence in managing unmet needs in hypertension treatment. AHA Lifelong Learning will achieve this goal by addressing educational needs and practice gaps that exist among a multidisciplinary team of HCPs involved in the care of patients with hypertension. The intervention will promote application of education into practice, providing learners with knowledge and skills they can put into practice immediately to impact patient outcomes.
- Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431
Agenda
- Spotlight Series: Unmet Needs in Hypertension Treatment Options - presentation
- Q & A
Presenter – Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Faculty
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Professor of Medicine, John W. Deming Department of Medicine
Tulane University School of Medicine
New Orleans, LA
Disclosure Policy
All persons in a position to control educational content of a CE activity provided by the American Heart Association must disclose to the audience all financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The presence or absence of all financial relationships will be disclosed to the audience in activity materials. All unlabeled/unapproved uses of drugs or devices discussed will also be disclosed to the audience. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Disclosures
The American Heart Association (AHA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its certified educational activities. All faculty, planners, and contributors in a position to control the content for an AHA sponsored activity are required to disclose to the activity audience any financial relationships regardless of the amount during the prior 24 months with (1) the manufacturer(s) of any ineligible company product(s) and/or interest(s) of ineligible companies regardless of relation to the content of the activity and (2) any ineligible company supporters of the activity. When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA – Consultant (Amgen, Novartis, Medtronic, Quantum Genomics, Janssen)
Accreditation Statement
ORIGINAL RELEASE DATE: 01/31/2023
TERMINATION DATE: 01/30/2024
LAST REVIEW DATE: November 2022
ACCREDITATION TERMS: Joint Accreditation: 01/31/2023 - 01/30/2024
In support of improving patient care, this activity has been planned and implemented by The American Heart Association. The American Heart Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA Credit Designation Statement – Physicians
The American Heart Association designates this enduring activity for a
maximum of 1.0 AMA PRA Category 1 Credits™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
MOC Statement
Successful completion of this CE activity, which includes participation in
the evaluation component, enables the participant to earn up to 1.0 MOC
points in the American Board of Internal Medicine's (ABIM) Maintenance of
Certification (MOC) program. Participants will earn MOC points equivalent to
the amount of CE credits claimed for the activity. It is the CE activity
provider's responsibility to submit participant completion information to
ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Acceptance Statement – Physician
Assistants
AAPA accepts certificates of participation for educational activities
certified for AMA PRA Category 1 Credit™ from
organizations accredited by ACCME or a recognized state medical society.
Physician assistants may receive a maximum of 1.0 hours of Category I credit
for completing this program.
AANP Credit Acceptance Statement – Nurse
Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA
Category 1 Credit™ from organizations accredited by the ACCME.
ANCC Credit Designation Statement – Nurses
The maximum number of hours awarded for this CE activity is 1.0 contact
hours.
Instructions for Receiving Credit
Participation and Successful
Completion
Successful completion of this CE activity includes the following:
- Register and view the course online.
- View the content in its entirety.
- Complete a post-test with a minimum score of 80%.
- Complete a survey of your learning experience.
- Claim your CME/CE Certificate.
Statement of Commercial Support
This activity is supported by an independent medical educational grant from Medtronic.
Disclaimer Statement/Disclosure of Unlabeled Use
When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.
Contact Information for Questions About the Activity
Luci Ochoa, MBA
Program Manager, Professional Education, AHA National Center
luci.ochoa@heart.org
Challenging Cases in Asthma: Optimizing Biologics in Adults
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
You have a middle-aged patient with severe, steroid-dependent asthma, multiple atopic comorbidities, and who has failed biologic after biologic for asthma. What do you do? Listen to what this expert, interprofessional panel recommends for collaborative care team management of this case and others that learners have submitted for their discussion.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Challenging Cases in Asthma: Improving Quality of Life
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 29, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
Allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
This interprofessional expert panel takes on challenging cases in severe and difficult-to-treat asthma, including pediatrics and non-T2 asthma. In their discussions they weigh different treatment strategies; consider atopic comorbidities; illustrate how asthma affects patients’ quality of life; and how they can work as a team to help optimize patient care from a pulmonology, allergy, and nursing perspective.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 100% on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Antibody-Mediated Rejection in Renal Transplantation: Immune Mechanisms, Diagnostic Criteria, & Therapeutic Advances: A Clinical Olympics℠
StartActivity Details
Expires: August 9, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians managing transplant patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the pathophysiology of chronic active antibody-mediated rejection (AMR) that leads to deleterious clinical manifestations in kidney transplant patients
- Apply Banff diagnostic criteria for chronic active AMR in renal allografts
- Examine the potential role of emerging therapeutic approaches in the management of chronic active AMR
Activity Description
Although over 100,000 renal transplants are performed worldwide each year, only a fraction of recipients are living with functioning renal grafts. Approximately 40% of renal transplants fail within 10 years. Chronic, or late, renal graft rejection is a leading cause of failure. Management of chronic active antibody-mediated rejection (AMR) is a major challenge due to the lack of both approved treatment options and clinical evidence informing current guidelines. In this fast-paced, highly interactive activity, Drs. Jordan, Djamali, and Schinstock will take you through the pathophysiology, diagnosis, and emerging therapeutics for chronic active AMR.
Chair
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Faculty
Chair, Department of Medicine
Maine Medical Center
Portland, ME
Associate Professor
Division of Nephrology and Hypertension
Mayo Clinic
Rochester, MN
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Arjang Djamali, MD, has relevant financial relationships with CareDX, CSL Behring (Advisor).
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Carrie A. Schinstock, MD, has relevant financial relationships with Alexion Pharmaceuticals, CSL Behring, Genentech, Sanofi (Researcher); CSL Behring (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in
the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION
FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
Expires: August 9, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians managing transplant patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the pathophysiology of chronic active antibody-mediated rejection (AMR) that leads to deleterious clinical manifestations in kidney transplant patients
- Apply Banff diagnostic criteria for chronic active AMR in renal allografts
- Examine the potential role of emerging therapeutic approaches in the management of chronic active AMR
Activity Description
Although over 100,000 renal transplants are performed worldwide each year, only a fraction of recipients are living with functioning renal grafts. Approximately 40% of renal transplants fail within 10 years. Chronic, or late, renal graft rejection is a leading cause of failure. Management of chronic active antibody-mediated rejection (AMR) is a major challenge due to the lack of both approved treatment options and clinical evidence informing current guidelines. In this fast-paced, highly interactive activity, Drs. Jordan, Djamali, and Schinstock will take you through the pathophysiology, diagnosis, and emerging therapeutics for chronic active AMR.
Chair
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Faculty
Chair, Department of Medicine
Maine Medical Center
Portland, ME
Associate Professor
Division of Nephrology and Hypertension
Mayo Clinic
Rochester, MN
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Arjang Djamali, MD, has relevant financial relationships with CareDX, CSL Behring (Advisor).
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Carrie A. Schinstock, MD, has relevant financial relationships with Alexion Pharmaceuticals, CSL Behring, Genentech, Sanofi (Researcher); CSL Behring (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim
only the credit commensurate with the extent of their participation in
the activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION
FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Reinforcing the Roles of Biologic Therapy and Interprofessional Care in Improving Patient Outcomes in Severe and Difficult-to-Control Asthma
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: July 24, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology and pulmonology clinicians engaged in the care of patients with asthma.
Learning Objectives
- Differentiate between phenotypes in patients with asthma according to pathogenic mechanisms and biomarkers
- Select an appropriate biologic therapy for patients with asthma based on disease severity and phenotype
- Integrate the unique roles of the interprofessional care team in the management of comorbidity and quality of life issues in patients with severe and difficult-to-treat asthma
Activity Description
Asthma is a heterogeneous disease involving multiple inflammatory pathways. While many patients can be successfully treated, others suffer from severe or difficult-to-control disease, compounded by multiple atopic conditions, and a poor quality of life. In this interprofessional panel, experts will discuss the different phenotypes and endotypes of asthma, how they affect therapy, the role of biologics in the treatment of severe or uncontrolled asthma, impact comorbid atopy can have on management and quality of life, and how we can work together as a healthcare team to manage severe and difficult-to-treat asthma.
Faculty
Professor, Medicine
Director, Cohen Family NJH Asthma Institute
Associate Vice President, Innovation and Industry Relations
Division of Pulmonary, Critical Care and Sleep Medicine
National Jewish Health
Denver, CO
Professor, Medicine
Cleveland Clinic Lerner College of Medicine
Chair, Department of Allergy and Clinical Immunology
Respiratory Institute, Cleveland Clinic
Cleveland, OH
Family Nurse Practitioner
Division of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
National Jewish Health
Denver, CO
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Rachel DeCosta, MSN, FNP-C, has no relevant financial relationship(s) with ineligible companies to disclose.
David M. Lang, MD, has relevant financial relationships with ARS Pharmaceuticals, AstraZeneca, Genentech, Novartis, Sanofi-Regeneron (Consultant, Other: Honoraria, Researcher).
Michael E. Wechsler, MD, MMSc, has relevant financial relationships with Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cerecor, Cohero Health, Cytoreason, Eli Lilly, Equillium, GSK, Incyte, Kinaset, Novartis, Phylaxis, Pulmatrix, RAPT Therapeutics, Regeneron, resTORbio, Roche/Genentech, Sanofi-Genzyme, Sentien Biotechnologies, Inc, Sound Biologics, TEVA, Upstream Bio (Consultant); Amgen, AstraZeneca, GSK, Regeneron, Sanofi-Genzyme (Speaker/Speaker’s Bureau).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
Planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 80% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at accreditation@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 80% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
An Integrated Approach to Chronic Active AMR in Renal Transplantation: Tying Together Pathogenesis, Diagnosis, and Emerging Treatment — Deciphering the Root Cause of Chronic Active Antibody-Mediated Rejection in Renal Transplant
StartActivity Details
Expires: June 6, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
- Employ established criteria to diagnose kidney transplant recipients with chronic active AMR
Activity Description
This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.
Faculty
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
Expires: June 6, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for transplant, nephrology, general surgery, and internal medicine clinicians involved in care of patients with antibody-mediated rejection (AMR).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Examine the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients
- Employ established criteria to diagnose kidney transplant recipients with chronic active AMR
Activity Description
This learner-friendly, 30-minute infographic activity is augmented by expert and patient videos with an interactive approach to examining the pathogenic mechanisms responsible for the deleterious clinical manifestations of chronic active antibody mediated-rejection (AMR) in kidney transplant recipients. Important highlights include risk factors and diagnostic criteria for chronic active AMR.
Faculty
Director, Nephrology & Transplant Immunology
Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Stanley C. Jordan, MD, FASN, FAST, has relevant financial relationships with Argenx, CareDx, CSL Behring, Hansa, Regeneron, Vera (Consultant); CSL Behring, Hansa, One Legacy (Grant/Research Support).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent educational grant from CSL Behring LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Words Matter – Terms to Use and Avoid When Talking About Addiction
StartActivity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Activity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity informs clinicians on how they can show leadership in how language can destigmatize the disease of addiction. It is focused on using person-first language, as well as terms to avoid to reduce stigma and negative bias when discussing addiction.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2678-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder
StartActivity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Describe the effects of stigma on pregnant women and mothers.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.
Activity Details
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Expires: October 17, 2023
Provided By
Target Audience
This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain the effects of stigmatizing language on patients with addiction.
- Describe the effects of stigma on pregnant women and mothers.
- Compare common terminology and assess which terms should be used or avoided and why.
- Integrate person-first, non-stigmatizing language into everyday practice.
- Identify terms to use and terms to avoid when speaking to patients about addiction.
Activity Description
This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.
Course Director
Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose.
The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.
Joint Accreditation Statement
In support
of improving patient care, this activity has been planned and implemented by
the Postgraduate Institute for Medicine and the National Institute on Drug
Abuse. Postgraduate Institute for Medicine is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a
maximum of 0.75 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.75 contact hour(s).
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education
activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council
for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge
Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA
CERP is a service of the American Dental Association to assist dental
professionals in identifying quality providers of continuing dental
education. ADA CERP does not approve or endorse individual courses or
instructors, nor does it imply acceptance of the credit hours by boards of
dentistry. Concerns or complaints about a CE provider may be directed to the
provider or to the Commission for Continuing Education Provider Recognition
at ADA.org/CERP.
Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).
Statement of Commercial Support
There is no commercial funding for this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Hardware/Software Requirements
Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
Contact Information for Questions About the Activity
If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.